Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

A retrospective cohort study developed and validated a predictive model for IgA nephropathy, using routinely available variables. 


IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation

A retrospective cohort in finerenone showed nearly 40% proteinuria reduction at 8 months and stable eGFR in patients with IgA nephropathy.


Finerenone Shows Promise in IgAN: Reduced Proteinuria, Stable Kidney Function 

Key FDA approvals, pivotal IgAN and glomerular trial results, and transplant and CKD insights from November 2025.


8 Nephrology Headlines You Missed in November 2025

The phase 2 study of ALXN2050 in IgAN did not meet its proteinuria endpoint, with emerging safety concerns and early termination.


Factor D Inhibition Lacks Efficacy For IgAN in Phase 2 ALXN2050 Trial, With Sayna Norouzi, MD 

FDA grants accelerated approval for sibeprenlimab for reducing proteinuria in IgA nephropathy.

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy 

Pediatric IgA nephropathy shows slow progression, high remission rates, and frequent relapse, with new risk factors identified to improve long-term prognosis and management.


New Evidence on Pediatric IgAN Progression Supports Need for Extended Follow-Up

A curated recap of 8 impactful trial updates from the American Society of Nephrology Kidney Week 2025.

Kidney Week 2025 Recap: 8 Trial Updates to Know in Nephrology

Non-RASi antihypertensive use before pregnancy in women with IgAN increased the risk of severe HDP and preterm delivery.


Pre-Conception Hypertension Linked to Adverse Pregnancy Outcomes in IgA Nephropathy

Dual BLyS/APRIL inhibition with telitacicept cut proteinuria and maintained kidney function in adults with IgA nephropathy.

Kidney Compass: Phase 3 Data on Telitacicept in IgA Nephropathy at ASN Kidney Week 2025

ASN insights on felzartamab, a CD38-targeted therapy, show sustained immune modulation in IgA nephropathy, offering a novel treatment approach.


PREVAIL: Felzartamab’s Sustained Clinical Outcomes In IgAN, With Jurgen Floege, MD

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.